American Century Companies Inc. grew its stake in shares of Oppenheimer Holdings Inc. (NYSE:OPY – Free Report) by 35.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 124,449 shares of the financial services provider’s stock after purchasing an additional 32,444 shares during the quarter. American Century Companies Inc. owned about 1.20% of Oppenheimer worth $5,962,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Quadrature Capital Ltd increased its holdings in shares of Oppenheimer by 31.3% during the 4th quarter. Quadrature Capital Ltd now owns 13,884 shares of the financial services provider’s stock worth $574,000 after acquiring an additional 3,308 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Oppenheimer during the 1st quarter worth approximately $1,293,000. Empowered Funds LLC increased its holdings in shares of Oppenheimer by 8.1% during the 1st quarter. Empowered Funds LLC now owns 37,191 shares of the financial services provider’s stock worth $1,485,000 after acquiring an additional 2,800 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Oppenheimer by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 284,885 shares of the financial services provider’s stock worth $11,373,000 after acquiring an additional 12,525 shares during the last quarter. Finally, EJF Capital LLC increased its holdings in shares of Oppenheimer by 12.4% during the 1st quarter. EJF Capital LLC now owns 40,000 shares of the financial services provider’s stock worth $1,597,000 after acquiring an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 32.26% of the company’s stock.
Oppenheimer Stock Down 0.1 %
OPY stock opened at $50.02 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 0.79 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $516.66 million, a PE ratio of 13.48 and a beta of 1.15. Oppenheimer Holdings Inc. has a 1-year low of $32.82 and a 1-year high of $58.35. The business’s 50 day simple moving average is $51.26 and its 200 day simple moving average is $46.00.
Oppenheimer Cuts Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 23rd. Shareholders of record on Friday, August 9th were issued a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 1.44%. The ex-dividend date of this dividend was Friday, August 9th. Oppenheimer’s dividend payout ratio is 19.41%.
Insider Buying and Selling at Oppenheimer
In other Oppenheimer news, insider Dennis P. Mcnamara sold 6,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $51.28, for a total value of $307,680.00. Following the transaction, the insider now directly owns 20,681 shares of the company’s stock, valued at approximately $1,060,521.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 32.49% of the company’s stock.
Oppenheimer Profile
Oppenheimer Holdings Inc operates as a middle-market investment bank and full-service broker-dealer in the Americas, Europe, the Middle East, and Asia. The company provides brokerage services covering corporate equity and debt securities, money market instruments, exchange-traded options and futures contracts, municipal bonds, mutual funds, exchange-traded funds, and unit investment trusts; financial and wealth planning services; and margin lending services.
Further Reading
- Five stocks we like better than Oppenheimer
- Best Stocks Under $5.00
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Where Do I Find 52-Week Highs and Lows?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Oppenheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oppenheimer and related companies with MarketBeat.com's FREE daily email newsletter.